Barclays (LON:BARC) analyst Steven Valiquette maintained a Hold rating on Henry Schein (NASDAQ:HSIC) on Tuesday, setting a price target of $69, which is approximately 2.33% above the present share price of $67.43.
Valiquette expects Henry Schein to post earnings per share (EPS) of $1.00 for the first quarter of 2021.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Henry Schein, with an average price target of $79.
The analysts price targets range from a high of $79 to a low of $79.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.84 billion and a net profit of $194.66 million. The company's market cap is $9.63 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.4% and a 53.16% success rate.
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.